The Autonomic Nervous System and Obesity

Condition(s) targeted: OBESITY; HYPERTENSION; PURE AUTONOMIC FAILURE; SHY-DRAGER SYNDROME

Intervention: Trimethaphan (Drug); Trimethaphan (Drug); Pseudoephedrine (Drug)

Phase: Phase 1/Phase 2

Status: Recruiting

Sponsored by: Vanderbilt University

Official(s) and/or principal investigator(s):
Italo Biaggioni, MD, Principal Investigator, Affiliation: Vanderbilt University

In its simplest terms, obesity is the results of a positive balance between food intake and energy expenditure (EE). I. e., we take in more energy, in the form of food, than we expend, e. g., by exercise. In our sedentary society, resting EE accounts for most of total energy expenditure. The sympathetic nervous system (SNS, the one that produces adrenaline) is thought to contribute to resting EE. This conclusion is based on experiments where resting EE is decreased by beta-blockers, high blood pressure medicines that block only one aspect of the sympathetic nervous system. The investigators propose to use a different approach, by using a medication called trimethaphan that produces transient withdrawal of the autonomic nervous system. The investigators will then compare the measured resting EE before and after SNS withdraw and quantify the degree of contribution to the resting EE by the SNS and delineate differences between healthy normal, healthy obese, and patients with autonomic dysfunctions.

Official title: The Autonomic Nervous System and Obesity

Study design: Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Primary outcome: Change in supine systolic blood pressure after achieving complete ganglionic blockade.

Secondary outcome: Change in resting energy expenditure after achieving complete autonomic blockade.

Detailed description: The rationale for this study is that even small alterations to energy metabolism can significantly change energy balance and body weight in the long term. We will test the hypothesis that the sympathetic nervous system (SNS) activity contributes to resting and thermogenic components of energy expenditure (EE). This study is divided in four different parts: (1), (2), (3), (4). Part (1): we will gauge the contribution of the sympathetic nervous system to resting energy expenditure, blood pressure, and determine differences between lean, obese, and patients with primary autonomic failure . Part (2): we will determine the degree of sympathetic blockade by a gradual infusion of the ganglionic blocker trimethaphan.[Part 2 has been closed] Part (3): we will determine the energy balance in patients with primary autonomic failure. Part (4): we will determine the contribution of the sympathetic nervous system to lipolysis.[Part 4 has been closed] Subjects selections*: For part (1) and (2) we will study six groups of subjects (n = 40 for each group): patients with pure autonomic failure, patients with multiple system atrophy, healthy normal controls (BMI <= 25), obese controls (BMI 30-40) and obese hypertensive (BMI 30-40) and lean hypertensive (BMI 20-28). A time interval of at least 1 week is required for those subjects who wish to participate in part (1) and part (2). For part (3) we will study two groups of subjects (n=12 for each group): patients with autonomic failure, and their age sex-matched sedentary, healthy controls. For part (4) we will study two groups of subjects (n=12 for each group): healthy normal controls (BMI 20-25), obese controls (BMI 30-40). *Part 2 and 4 have been closed.

Minimum age: 18 Years. Maximum age: 80 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Healthy normal (BMI <= 25 Kg/m2), obese (BMI between 30 and 40)volunteers, lean

hypertensive (BMI 20-28 Kg/m2), and obese hypertensive (BMI between 30 and 40)

- Ages 18-60

- Patients with pure autonomic failure and multiple system atrophy ages 18-80, referred

to our service for the diagnosis and treatment of their condition, and their age sex-matched sedentary, healthy controls ages 18-80 Exclusion criteria:

- All medical students

- Pregnant women

- Heart failure, symptomatic coronary artery disease, liver impairment, history of

stroke or myocardial infarction, glaucoma

- History of serious allergies or asthma

- Subjects using beta-blockers

Vanderbilt University, Nashville, Tennessee 37232, United States; Recruiting
Ginnie M Farley, RAIII, Email: adcresearch@vanderbilt.edu
Cyndya A Shibao, MD, Email: adcresearch@vanderbilt.edu
Italo Biaggioni, MD, Principal Investigator
Cyndya A Shibao, MD, Sub-Investigator
Alfredo Gamboa, MD, Sub-Investigator
Andre Diedrich, MD PhD, Sub-Investigator
Andrew Ertl, PhD, Sub-Investigator
Kong Chen, PhD, Sub-Investigator
Luis E okamoto, Sub-Investigator

Autonomic dysfunction center at Vanderbilt University

Starting date: April 2003
Last updated: May 21, 2015